# A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

> **NCT07014540** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Neuroendocrine Carcinomas (NEC)

## Interventions

- **DRUG:** Irinotecan Hydrochloride Liposome Injection
- **DRUG:** 5-FU
- **DRUG:** LV

## Key facts

- **NCT ID:** NCT07014540
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014540, "A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07014540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*